Sawai Group Holdings Co., Ltd.

4887.T
Drug Manufacturers - Specialty & Generic
2026/11/11 12:12 Updated
Market Cap: $1.2B (¥194.1B)
Stock Price: $10.60 (¥1,681)
Exchange Rate: 1 USD = ¥158.48

Notice of Revision to Earnings Guidance

While revenue guidance is planned to be revised upward, operating profit and net profit are significantly revised downward. Interim and full-year forecasts have been reviewed, and treatment of discontinued operations is noted. No revision to dividend forecast.

Importance:
Page Updated: November 11, 2026
IR Disclosure Date: November 11, 2026

Key Figures

  • Revenue (Q2): 102,000 million yen
  • Basic Interim Net Income Attributable to Owners of Parent per Share: 42.62 yen
  • Full-year Revenue: 212,700 million yen

AI要約

Overview of Revision to Earnings Guidance

The consolidated earnings guidance for the second quarter (interim) and full fiscal year has been revised. Revenue is expected to exceed the previous forecast, but core operating income, operating income, profit before tax and interim net income attributable to owners of parent are each significantly revised downward. The impacts include product portfolio review, demand softening after lifting of restricted shipments, rising raw material costs and decreased production efficiency leading to higher costs. There is no revision to the dividend forecast.

Outlook and Factors Going Forward

The treatment of figures related to discontinued operations is clarified. The U.S. business is classified as a discontinued operation and will be presented alongside metrics for continuing operations. Demand weakness and higher costs are expected to pressure profits; although efforts to control selling, general and administrative expenses will continue, they may not fully offset profit declines. Future focus will be on trends in cost ratios and improvements in production efficiency.

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Sawai Group Holdings Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →